Automated classification of perfusion maps enabled us to distinguish patients with various stages of Alzheimer disease with high accuracy.

Purpose

To investigate whether multivariate pattern recognition analysis of arterial spin labeling (ASL) perfusion maps can be used for classification and single-subject prediction of patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) and subjects with subjective cognitive decline (SCD) after using the W score method to remove confounding effects of sex and age.

Materials and Methods

Pseudocontinuous 3.0-T ASL images were acquired in 100 patients with probable AD; 60 patients with MCI, of whom 12 remained stable, 12 were converted to a diagnosis of AD, and 36 had no follow-up; 100 subjects with SCD; and 26 healthy control subjects. The AD, MCI, and SCD groups were divided into a sex- and age-matched training set (n = 130) and an independent prediction set (n = 130). Standardized perfusion scores adjusted for age and sex (W scores) were computed per voxel for each participant. Training of a support vector machine classifier was performed with diagnostic status and perfusion maps. Discrimination maps were extracted and used for single-subject classification in the prediction set. Prediction performance was assessed with receiver operating characteristic (ROC) analysis to generate an area under the ROC curve (AUC) and sensitivity and specificity distribution.

Results

Single-subject diagnosis in the prediction set by using the discrimination maps yielded excellent performance for AD versus SCD (AUC, 0.96; P < .01), good performance for AD versus MCI (AUC, 0.89; P < .01), and poor performance for MCI versus SCD (AUC, 0.63; P = .06). Application of the AD versus SCD discrimination map for prediction of MCI subgroups resulted in good performance for patients with MCI diagnosis converted to AD versus subjects with SCD (AUC, 0.84; P < .01) and fair performance for patients with MCI diagnosis converted to AD versus those with stable MCI (AUC, 0.71; P > .05).

Conclusion

With automated methods, age- and sex-adjusted ASL perfusion maps can be used to classify and predict diagnosis of AD, conversion of MCI to AD, stable MCI, and SCD with good to excellent accuracy and AUC values.

© RSNA, 2016

References

  • 1. Alzheimer’s Association. 2014 Alzheimer’s disease facts and figures. Alzheimers Dement 2014;10(2):e47–e92.

  • 2. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61(4):1–117.
  • 3. Morinaga A, Ono K, Ikeda T, et al. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer’s disease in a memory clinic. Dement Geriatr Cogn Disord 2010;30(4):285–292.
  • 4. Filippi M, Agosta F, Barkhof F, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012;19(12):e131–e140, 1487–1501.
  • 5. Viola KL, Sbarboro J, Sureka R, et al. Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease. Nat Nanotechnol 2015;10(1):91–98.
  • 6. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9(1):119–128.
  • 7. Binnewijzend MA, Kuijer JP, van der Flier WM, et al. Distinct perfusion patterns in Alzheimer’s disease, frontotemporal dementia and dementia with Lewy bodies. Eur Radiol 2014;24(9):2326–2333.
  • 8. Binnewijzend MA, Kuijer JP, Benedictus MR, et al. Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology 2013;267(1):221–230.
  • 9. Wolk DA, Detre JA. Arterial spin labeling MRI: an emerging biomarker for Alzheimer’s disease and other neurodegenerative conditions. Curr Opin Neurol 2012;25(4):421–428.
  • 10. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009;250(3):856–866.
  • 11. Binnewijzend MA, Benedictus MR, Kuijer JP, et al. Cerebral perfusion in the predementia stages of Alzheimer’s disease. Eur Radiol 2016;26(2):506–514.
  • 12. Gray KR, Wolz R, Heckemann RA, et al. Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer’s disease. Neuroimage 2012;60(1):221–229.
  • 13. Detre JA, Leigh JS, Williams DS, Koretsky AP. Perfusion imaging. Magn Reson Med 1992;23(1):37–45.
  • 14. Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 2015;73(1):102–116.
  • 15. Chen Y, Wolk DA, Reddin JS, et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011;77(22):1977–1985.
  • 16. Verfaillie S, Adriaanse SM, Binnewijzend M, et al. Resting state cerebral perfusion and metabolism in subjective memory complaints: Alzheimer’s disease and frontotemporal dementia—two sides of the same coin? Alzheimers Dement 2014;10(4 Suppl):P543.
  • 17. Klöppel S, Stonnington CM, Chu C, et al. Automatic classification of MR scans in Alzheimer’s disease. Brain 2008;131(Pt 3):681–689.
  • 18. Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer’s disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008;39(3):1186–1197.
  • 19. DeCarli C, Frisoni GB, Clark CM, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007;64(1):108–115.
  • 20. Teipel SJ, Born C, Ewers M, et al. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer’s disease in mild cognitive impairment. Neuroimage 2007;38(1):13–24.
  • 21. Schrouff J, Rosa MJ, Rondina JM, et al. PRoNTo: pattern recognition for neuroimaging toolbox. Neuroinformatics 2013;11(3):319–337.
  • 22. O’Brien PC, Dyck PJ. Procedures for setting normal values. Neurology 1995;45(1):17–23.
  • 23. La Joie R, Perrotin A, Barré L, et al. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer’s disease dementia. J Neurosci 2012;32(46):16265–16273.
  • 24. van der Flier WM, Pijnenburg YA, Prins N, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis 2014;41(1):313–327.
  • 25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34(7):939–944.
  • 26. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56(3):303–308.
  • 27. Verhage F. Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventigjaar [thesis]. Assen, the Netherlands: Van Gorcum, 1964.
  • 28. Buxton RB, Frank LR, Wong EC, Siewert B, Warach S, Edelman RR. A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med 1998;40(3):383–396.
  • 29. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208–S219.
  • 30. Pase MP, Grima NA, Stough C, Scholey A, Pipingas A. Association of pulsatile and mean cerebral blood flow velocity with age and neuropsychological performance. Physiol Behav 2014;130:23–27.
  • 31. Vapnik V. The nature of statistical learning theory. New York, NY: Springer Verlag, 1995.
  • 32. Kukull WA, Ganguli M. Generalizability: the trees, the forest, and the low-hanging fruit. Neurology 2012;78(23):1886–1891.
  • 33. Klöppel S, Abdulkadir A, Jack CR Jr, Koutsouleris N, Mourão-Miranda J, Vemuri P. Diagnostic neuroimaging across diseases. Neuroimage 2012;61(2):457–463.
  • 34. Kim EJ, Cho SS, Jeong Y, et al. Glucose metabolism in early onset versus late onset Alzheimer’s disease: an SPM analysis of 120 patients. Brain 2005;128(Pt 8):1790–1801.
  • 35. Kemp PM, Holmes C, Hoffmann SM, et al. Alzheimer’s disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia. J Neurol Neurosurg Psychiatry 2003;74(6):715–719.

Article History

Received December 9, 2015; revision requested January 19, 2016; revision received March 11; accepted March 18; final version accepted April 6.
Published online: July 06 2016
Published in print: Dec 2016